What is HC Wainwright’s Forecast for ATNM FY2028 Earnings?

Posted by Brenda Bartman on Jun 5th, 2026

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Free Report) – Analysts at HC Wainwright lifted their FY2028 earnings per share estimates for shares of Actinium Pharmaceuticals in a research note issued to investors on Wednesday, June 3rd. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.69) per share for the year, up from their prior estimate of ($0.86). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

Separately, Stephens restated an “overweight” rating and set a $5.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, March 31st. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $4.50.

View Our Latest Report on Actinium Pharmaceuticals

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock opened at $1.11 on Friday. The stock has a market capitalization of $34.83 million, a PE ratio of -0.80 and a beta of -0.06. Actinium Pharmaceuticals has a 1-year low of $0.95 and a 1-year high of $1.95. The business has a 50-day moving average of $1.19 and a 200 day moving average of $1.26.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Actinium Pharmaceuticals by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after buying an additional 12,703 shares during the period. Renaissance Technologies LLC lifted its holdings in Actinium Pharmaceuticals by 20.7% in the 1st quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock worth $469,000 after buying an additional 80,816 shares during the period. Two Sigma Investments LP lifted its holdings in Actinium Pharmaceuticals by 403.4% in the 3rd quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after buying an additional 187,748 shares during the period. Jane Street Group LLC purchased a new stake in Actinium Pharmaceuticals in the 2nd quarter worth approximately $306,000. Finally, Marshall Wace LLP purchased a new stake in Actinium Pharmaceuticals in the 2nd quarter worth approximately $137,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.